首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro
【2h】

Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro

机译:西多福韦和环西多福韦的烷氧基烷基酯对巨细胞病毒和疱疹病毒的体外抗病毒活性的多对数增强。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The incidence of cytomegalovirus (CMV) retinitis is declining in AIDS patients but remains a significant clinical problem in patients with organ transplants and bone marrow transplants. Prophylaxis with ganciclovir (GCV) or valganciclovir reduces the incidence of CMV disease but may lead to the emergence of drug-resistant virus with mutations in the UL97 or UL54 gene. It would be useful to have other types of oral therapy for CMV disease. We synthesized hexadecyloxypropyl and octadecyloxyethyl derivatives of cyclic cidofovir (cCDV) and cidofovir (CDV) and found that these novel analogs had 2.5- to 4-log increases in antiviral activity against CMV compared to the activities of unmodified CDV and cCDV. Multiple-log increases in activity were noted against laboratory CMV strains and various CMV clinical isolates including GCV-resistant strains with mutations in the UL97 and UL54 genes. Preliminary cell studies suggest that the increase in antiviral activity may be partially explained by a much greater cell penetration of the novel analogs. 1-O-Hexadecyloxypropyl-CDV, 1-O-octadecyloxyethyl-CDV, and their corresponding cCDV analogs are worthy of further preclinical evaluation for treatment and prevention of CMV and herpes simplex virus infections in humans.
机译:艾滋病患者中巨细胞病毒(CMV)视网膜炎的发病率正在下降,但在器官移植和骨髓移植患者中,仍然是一个重大的临床问题。更昔洛韦(GCV)或缬更昔洛韦的预防可降低CMV疾病的发生率,但可能导致出现UL97或UL54基因突变的耐药病毒。对于CMV疾病,具有其他类型的口服疗法将是有用的。我们合成了环西多福韦(cCDV)和西多福韦(CDV)的十六烷基氧丙基和十八烷基氧乙基衍生物,发现与未修饰的CDV和cCDV的活性相比,这些新型类似物对CMV的抗病毒活性提高了2.5至4个对数。注意到针对实验室CMV菌株和各种CMV临床分离株(包括在UL97和UL54基因中具有突变的GCV耐药株)的活性呈多对数增长。初步的细胞研究表明,抗病毒活性的提高可以部分通过新型类似物的更大的细胞渗透来解释。 1-O-十六烷基氧基丙基-CDV,1-O-十八烷基氧基乙基-CDV及其相应的cCDV类似物值得进一步临床前评估,用于治疗和预防人的CMV和单纯疱疹病毒感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号